Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 15:10.1111/epi.18460.
doi: 10.1111/epi.18460. Online ahead of print.

Time to prerandomization seizure count design sufficiently assessed the safety and tolerability of perampanel for the treatment of focal seizures

Wesley T Kerr  1   2 , Leock Y Ngo  3   4 , Liang Zhu  5 , Anna Patten  6 , Jocelyn Y Cheng  5 , Lavanya Biju  1 , Jacqueline A French  7
Affiliations

Time to prerandomization seizure count design sufficiently assessed the safety and tolerability of perampanel for the treatment of focal seizures

Wesley T Kerr et al. Epilepsia. .

Abstract

Objective: In traditionally designed randomized clinical trials of antiseizure medications, participants take a blinded treatment for a prespecified number of weeks, irrespective of continued seizures. The alternative design time to prerandomization monthly seizure count (T-PSC) allows participants to end the blinded treatment after an individually prespecified number of seizures, which shortens exposure to placebo and ineffective treatment. Previous reanalyses have shown that T-PSC replicated the efficacy conclusions of trials; therefore, we evaluated whether T-PSC also could replicate tolerability and safety conclusions.

Methods: We retrospectively applied the T-PSC design to analyze treatment-emergent adverse events (TEAEs) from three blinded, placebo-controlled trials of perampanel for focal onset seizures (NCT00699972, NCT00699582, NCT00700310). We evaluated the incidences of TEAEs, treatment-related TEAEs, serious TEAEs, and TEAEs that prompted medication adjustment compared to those observed during the full-length trial.

Results: Of the 1480 participants in the three trials, 1093 experienced any TEAE, of whom 1006 (92%) had onset prior to T-PSC. When evaluating the differences in each type of TEAE for each dose of perampanel from placebo within each trial, there was no consistent pattern of under- or overestimation. Across the three studies, 23 of 79 (29%) serious TEAEs, most requiring hospitalization, occurred after T-PSC.

Significance: Almost all TEAEs occurred before T-PSC. Similar conclusions regarding the tolerability and safety of perampanel would have been reached if the T-PSC design had been used. This suggests that the T-PSC design may potentially benefit participants by allowing earlier change from an ineffective treatment to an alternate treatment, which could reduce the risk of serious consequences of ineffective treatment, such as hospitalization.

Keywords: clinical trials; epilepsy; survival analysis; time to event; trial design.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Kerr WT, et al. , Time-to-event clinical trial designs: Existing evidence and remaining concerns. Epilepsia, 2023. 64(7): p. 1699–1708. - PMC - PubMed
    1. Ryvlin P, Cucherat M, and Rheims S, Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol, 2011. 10(11): p. 961–8. - PubMed
    1. Kerr WT, et al. , Increasing challenges to trial recruitment and conduct over time. Epilepsia, 2023. 64(10): p. 2625–2634. - PMC - PubMed
    1. Kerr WT, et al. , Reasons for ineligibility for clinical trials of patients with medication resistant epilepsy. Epilepsia, 2023. 64(6): p. e56–e60. - PubMed
    1. French JA, et al. , Time to prerandomization monthly seizure count in perampanel trials: A novel epilepsy endpoint. Neurology, 2015. 84(20): p. 2014–20. - PMC - PubMed

LinkOut - more resources